EBMT 2019 | FLT3 inhibitors as a strategy to treat AML

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses the promising role of FLT3 inhibitors for FLT3-mutated acute myeloid leukemia (AML). Mentioning the encouraging survival outcomes in patients treated with agents such as midostaurin, quizartinib and sorafenib, Prof. Craddock also reports the potential of FLT3 inhibitors as being effective maintenance therapies post-transplant. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Share this video